Projects
KOTK Novel combination therapies to combat therapy resistant neuroblastoma: translating preclinical investigations to clinical trials. KU Leuven
The aims of this project are two-fold: (1) further evaluate the efficacy and toxicity of nutlin, alectinib, palbociclib, silvestrol and TMPYP4 in combination with currently used chemotherapeutic agents in neuroblastoma treatment, including cisplatin, cyclophosphamide, doxorubicin, etoposide, vincristine, topotecan, irinotecan, temozolomide and busulfan using in vitro cell line experiments and xenograft cell line models and (2) to determine ...
Novel combination therapies to combat therapy resistant neuroblastoma: translating pre-clinical investigations to clinical trials Ghent University
Neuroblastoma is an aggressive paediatric solid tumour originating from the sympathetic nervous system. New combination therapies are urgently warranted as high-risk neuroblastoma has a poor prognosis.
The aims of this project are two-fold: (1) further evaluate the efficacy and toxicity of nutlin, alectinib, palbociclib, silvestrol and TMPYP4 in combination with currently used chemotherapeutic agents in neuroblastoma treatment (2) to ...
Existential empathy: An identifiable therapist variable contributing to therapy outcome KU Leuven
The cystic fibrosis lung in the era of modulator therapy: a longitudinal study of the lung bacterial and fungal microbiome and improving personalized phage therapy to treat multi-drug resistant infections Ghent University
Background and objectives
Modulator therapy in cystic fibrosis (CF) has led to a substantial clinical improvement of the CF patient population. However, there is currently lack of data and no consensus regarding the long-term impact of modulators on the lung microbiome and infections. Studies are often limited by the lack microbiological resolution, focus on single pathogens and none studied the Belgian CF population. Importantly, no ...
Personalized immune therapy: FAP as a marker for resistance to immune checkpoint therapy in urothelial carcinomas. University of Antwerp
Multiple myeloma tumor microenvironment characterization in relation to its response to glucocorticoid therapy: from biomarkers to an improved therapy Ghent University
Glucocorticoids are a cornerstone in the treatment of multiple myeloma, a plasma cell malignancy located in the bone marrow. Prolonged treatment with glucocorticoids leads to GC resistance. We aim to establish novel mechanistic insights in GC resistance development by studying the link between the onset of GC resistance and a dysfunctional GR signaling pathway.
Anti-kanker therapie versterkt door kleine radioactief gelabelde compounds met affiniteit voor necrosis (sRALNAC): een Prrof-of-Principle experiment ter ondersteuning van een nieuw patent aanvraag. KU Leuven
Oncogenese en resistentie tegen therapie bij bloedkankers begrijpen en gerichten Ghent University
Acute leukemia, both of myeloid and lymphoid origin, is a very prevalent cancer in kids and adults. Unfortunately, frontline radiation and chemotherapy causes lasting cognitive problems and can also lead to secondary cancers. Additionally, about one-fourth of children and 50% of adults with acute leukemia develop resistance to therapy or relapse post therapy.
Mechanisms of resistance are poorly understood and current research on ...
AcCEPT:adaptive cost effective proton therapie KU Leuven
External beam radiotherapy aims at delivering a curative dose to tumours while safeguarding healthy tissues. In the lung, this objective is challenged by the close presence of critical organs and breathing motion.Protons display appealing features to help reaching that goal: they show a reduced dose before a steep rise immediately followed by a sharp fall-off (Bragg-peak&rdquo). The precision ot the Bragg peak yields its major challenge: ...